JP2020508694A5 - - Google Patents

Info

Publication number

JP2020508694A5

JP2020508694A5 JP2019557693A JP2019557693A JP2020508694A5 JP 2020508694 A5 JP2020508694 A5 JP 2020508694A5 JP 2019557693 A JP2019557693 A JP 2019557693A JP 2019557693 A JP2019557693 A JP 2019557693A JP 2020508694 A5 JP2020508694 A5 JP 2020508694A5

Authority

JP

Japan

Prior art keywords

seq

nos

cdr

antibody

erbb2

Prior art date

2018-01-04

Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)

Granted

Links

• Espacenet
• Global Dossier
• Discuss

• 229960000575 trastuzumab Drugs 0.000 claims description 242
• 101150029707 ERBB2 gene Proteins 0.000 claims description 241
• 210000004027 cell Anatomy 0.000 claims description 196
• 102000014914 Carrier Proteins Human genes 0.000 claims description 144
• 108091008324 binding proteins Proteins 0.000 claims description 144
• 230000027455 binding Effects 0.000 claims description 109
• 206010028980 Neoplasm Diseases 0.000 claims description 102
• 239000000427 antigen Substances 0.000 claims description 89
• 102000036639 antigens Human genes 0.000 claims description 83
• 108091007433 antigens Proteins 0.000 claims description 83
• 229960002087 pertuzumab Drugs 0.000 claims description 69
• 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 60
• 239000003814 drug Substances 0.000 claims description 53
• 238000011282 treatment Methods 0.000 claims description 51
• 239000012634 fragment Substances 0.000 claims description 49
• 239000003795 chemical substances by application Substances 0.000 claims description 42
• 229940079593 drug Drugs 0.000 claims description 41
• 230000000694 effects Effects 0.000 claims description 40
• 201000010099 disease Diseases 0.000 claims description 31
• 208000035475 disorder Diseases 0.000 claims description 29
• 201000011510 cancer Diseases 0.000 claims description 25
• 230000002401 inhibitory effect Effects 0.000 claims description 25
• 206010006187 Breast cancer Diseases 0.000 claims description 21
• 208000026310 Breast neoplasm Diseases 0.000 claims description 21
• 108060003951 Immunoglobulin Proteins 0.000 claims description 21
• 102000018358 immunoglobulin Human genes 0.000 claims description 21
• 230000001404 mediated effect Effects 0.000 claims description 19
• AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 claims description 18
• 239000002246 antineoplastic agent Substances 0.000 claims description 18
• 230000012010 growth Effects 0.000 claims description 16
• 108090000765 processed proteins & peptides Proteins 0.000 claims description 16
• GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 claims description 15
• 239000008194 pharmaceutical composition Substances 0.000 claims description 15
• 229940127089 cytotoxic agent Drugs 0.000 claims description 14
• 239000003937 drug carrier Substances 0.000 claims description 14
• 208000005718 Stomach Neoplasms Diseases 0.000 claims description 12
• 102000004196 processed proteins & peptides Human genes 0.000 claims description 12
• 206010017758 gastric cancer Diseases 0.000 claims description 11
• 201000011549 stomach cancer Diseases 0.000 claims description 11
• 108090000695 Cytokines Proteins 0.000 claims description 10
• 102000004127 Cytokines Human genes 0.000 claims description 10
• 150000001413 amino acids Chemical group 0.000 claims description 10
• 229920001184 polypeptide Polymers 0.000 claims description 10
• 239000013598 vector Substances 0.000 claims description 10
• 239000005557 antagonist Substances 0.000 claims description 9
• 239000002254 cytotoxic agent Substances 0.000 claims description 9
• 231100000599 cytotoxic agent Toxicity 0.000 claims description 9
• 108091033319 polynucleotide Proteins 0.000 claims description 9
• 239000002157 polynucleotide Substances 0.000 claims description 9
• 102000040430 polynucleotide Human genes 0.000 claims description 9
• 230000001627 detrimental effect Effects 0.000 claims description 8
• SDUQYLNIPVEERB-QPPQHZFASA-N gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 claims description 7
• 229940072221 immunoglobulins Drugs 0.000 claims description 7
• 229940126619 mouse monoclonal antibody Drugs 0.000 claims description 7
• 229940124597 therapeutic agent Drugs 0.000 claims description 7
• UCTWMZQNUQWSLP-VIFPVBQESA-N (R)-adrenaline Chemical compound CNC[C@H](O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-VIFPVBQESA-N 0.000 claims description 6
• 102000009786 Immunoglobulin Constant Regions Human genes 0.000 claims description 6
• 108010009817 Immunoglobulin Constant Regions Proteins 0.000 claims description 6
• FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 claims description 6
• 229930012538 Paclitaxel Natural products 0.000 claims description 6
• 239000003246 corticosteroid Substances 0.000 claims description 6
• 229960004679 doxorubicin Drugs 0.000 claims description 6
• 229960000485 methotrexate Drugs 0.000 claims description 6
• 229960001592 paclitaxel Drugs 0.000 claims description 6
• 208000015608 reproductive system cancer Diseases 0.000 claims description 6
• RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 claims description 6
• PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 claims description 5
• 229930105110 Cyclosporin A Natural products 0.000 claims description 5
• 108010036949 Cyclosporine Proteins 0.000 claims description 5
• ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 claims description 5
• 229960001265 ciclosporin Drugs 0.000 claims description 5
• 229930182912 cyclosporin Natural products 0.000 claims description 5
• 230000001419 dependent effect Effects 0.000 claims description 5
• 229960003668 docetaxel Drugs 0.000 claims description 5
• 229960002949 fluorouracil Drugs 0.000 claims description 5
• 239000012216 imaging agent Substances 0.000 claims description 5
• 230000003053 immunization Effects 0.000 claims description 5
• 239000003112 inhibitor Substances 0.000 claims description 5
• 230000001766 physiological effect Effects 0.000 claims description 5
• 230000035755 proliferation Effects 0.000 claims description 5
• ZAHRKKWIAAJSAO-UHFFFAOYSA-N rapamycin Natural products COCC(O)C(=C/C(C)C(=O)CC(OC(=O)C1CCCCN1C(=O)C(=O)C2(O)OC(CC(OC)C(=CC=CC=CC(C)CC(C)C(=O)C)C)CCC2C)C(C)CC3CCC(O)C(C3)OC)C ZAHRKKWIAAJSAO-UHFFFAOYSA-N 0.000 claims description 5
• 229960002930 sirolimus Drugs 0.000 claims description 5
• QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 claims description 5
• 190000008236 Carboplatin Chemical compound 0.000 claims description 4
• 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 4
• 208000029052 T-cell acute lymphoblastic leukemia Diseases 0.000 claims description 4
• 230000033115 angiogenesis Effects 0.000 claims description 4
• 239000004037 angiogenesis inhibitor Substances 0.000 claims description 4
• 229940034982 antineoplastic agent Drugs 0.000 claims description 4
• 229960004562 carboplatin Drugs 0.000 claims description 4
• 229960004316 cisplatin Drugs 0.000 claims description 4
• DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 claims description 4
• 229960001334 corticosteroids Drugs 0.000 claims description 4
• 210000004996 female reproductive system Anatomy 0.000 claims description 4
• 229960005277 gemcitabine Drugs 0.000 claims description 4
• 238000002649 immunization Methods 0.000 claims description 4
• 201000005202 lung cancer Diseases 0.000 claims description 4
• 208000020816 lung neoplasm Diseases 0.000 claims description 4
• 230000000938 luteal effect Effects 0.000 claims description 4
• 201000006417 multiple sclerosis Diseases 0.000 claims description 4
• -1 selecoxib Chemical compound 0.000 claims description 4
• 208000011580 syndromic disease Diseases 0.000 claims description 4
• 229930182837 (R)-adrenaline Natural products 0.000 claims description 3
• VVIAGPKUTFNRDU-UHFFFAOYSA-N 6S-folinic acid Natural products C1NC=2NC(N)=NC(=O)C=2N(C=O)C1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 VVIAGPKUTFNRDU-UHFFFAOYSA-N 0.000 claims description 3
• 206010003445 Ascites Diseases 0.000 claims description 3
• 229940123780 DNA topoisomerase I inhibitor Drugs 0.000 claims description 3
• 229940124087 DNA topoisomerase II inhibitor Drugs 0.000 claims description 3
• 239000005411 L01XE02 - Gefitinib Substances 0.000 claims description 3
• 239000000365 Topoisomerase I Inhibitor Substances 0.000 claims description 3
• 239000000317 Topoisomerase II Inhibitor Substances 0.000 claims description 3
• 229940009456 adriamycin Drugs 0.000 claims description 3
• 239000003263 anabolic agent Substances 0.000 claims description 3
• 229940070021 anabolic steroids Drugs 0.000 claims description 3
• 229940121369 angiogenesis inhibitor Drugs 0.000 claims description 3
• 229940045799 anthracyclines and related substance Drugs 0.000 claims description 3
• 239000000935 antidepressant agent Substances 0.000 claims description 3
• 229940005513 antidepressants Drugs 0.000 claims description 3
• 239000004599 antimicrobial Substances 0.000 claims description 3
• 239000003435 antirheumatic agent Substances 0.000 claims description 3
• 208000006673 asthma Diseases 0.000 claims description 3
• 229940125388 beta agonist Drugs 0.000 claims description 3
• 229940111134 coxibs Drugs 0.000 claims description 3
• 239000003255 cyclooxygenase 2 inhibitor Substances 0.000 claims description 3
• 230000007850 degeneration Effects 0.000 claims description 3
• 229960005139 epinephrine Drugs 0.000 claims description 3
• VVIAGPKUTFNRDU-ABLWVSNPSA-N folinic acid Chemical compound C1NC=2NC(N)=NC(=O)C=2N(C=O)C1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 VVIAGPKUTFNRDU-ABLWVSNPSA-N 0.000 claims description 3
• 235000008191 folinic acid Nutrition 0.000 claims description 3
• 239000011672 folinic acid Substances 0.000 claims description 3
• 229960002584 gefitinib Drugs 0.000 claims description 3
• XGALLCVXEZPNRQ-UHFFFAOYSA-N gefitinib Chemical compound C=12C=C(OCCCN3CCOCC3)C(OC)=CC2=NC=NC=1NC1=CC=C(F)C(Cl)=C1 XGALLCVXEZPNRQ-UHFFFAOYSA-N 0.000 claims description 3
• 229940020967 gemzar Drugs 0.000 claims description 3
• 239000000122 growth hormone Substances 0.000 claims description 3
• 239000005556 hormone Substances 0.000 claims description 3
• 229940088597 hormone Drugs 0.000 claims description 3
• 229960003444 immunosuppressant agent Drugs 0.000 claims description 3
• 239000003018 immunosuppressive agent Substances 0.000 claims description 3
• 229960004768 irinotecan Drugs 0.000 claims description 3
• UWKQSNNFCGGAFS-XIFFEERXSA-N irinotecan Chemical compound C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1 UWKQSNNFCGGAFS-XIFFEERXSA-N 0.000 claims description 3
• 229940043355 kinase inhibitor Drugs 0.000 claims description 3
• 229960001691 leucovorin Drugs 0.000 claims description 3
• 239000003589 local anesthetic agent Substances 0.000 claims description 3
• 239000003158 myorelaxant agent Substances 0.000 claims description 3
• 239000000842 neuromuscular blocking agent Substances 0.000 claims description 3
• 239000003757 phosphotransferase inhibitor Substances 0.000 claims description 3
• 239000012217 radiopharmaceutical Substances 0.000 claims description 3
• 229940121896 radiopharmaceutical Drugs 0.000 claims description 3
• 230000002799 radiopharmaceutical effect Effects 0.000 claims description 3
• 239000000932 sedative agent Substances 0.000 claims description 3
• 150000003431 steroids Chemical class 0.000 claims description 3
• VEEGZPWAAPPXRB-BJMVGYQFSA-N (3e)-3-(1h-imidazol-5-ylmethylidene)-1h-indol-2-one Chemical compound O=C1NC2=CC=CC=C2\C1=C/C1=CN=CN1 VEEGZPWAAPPXRB-BJMVGYQFSA-N 0.000 claims description 2
• 229940088872 Apoptosis inhibitor Drugs 0.000 claims description 2
• 102100021569 Apoptosis regulator Bcl-2 Human genes 0.000 claims description 2
• 206010003210 Arteriosclerosis Diseases 0.000 claims description 2
• 101150017888 Bcl2 gene Proteins 0.000 claims description 2
• 101150008012 Bcl2l1 gene Proteins 0.000 claims description 2
• 206010004446 Benign prostatic hyperplasia Diseases 0.000 claims description 2
• 206010004593 Bile duct cancer Diseases 0.000 claims description 2
• 208000003174 Brain Neoplasms Diseases 0.000 claims description 2
• 208000010482 CADASIL Diseases 0.000 claims description 2
• 208000033221 Cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy Diseases 0.000 claims description 2
• 208000033935 Cerebral autosomal dominant arteriopathy-subcortical infarcts-leukoencephalopathy Diseases 0.000 claims description 2
• 206010009944 Colon cancer Diseases 0.000 claims description 2
• 208000011231 Crohn disease Diseases 0.000 claims description 2
• 239000012624 DNA alkylating agent Substances 0.000 claims description 2
• 201000009273 Endometriosis Diseases 0.000 claims description 2
• 208000000461 Esophageal Neoplasms Diseases 0.000 claims description 2
• 101600132127 Homo sapiens Receptor tyrosine-protein kinase erbB-2 (isoform 1) Proteins 0.000 claims description 2
• 206010021042 Hypopharyngeal cancer Diseases 0.000 claims description 2
• 206010056305 Hypopharyngeal neoplasm Diseases 0.000 claims description 2
• 208000022559 Inflammatory bowel disease Diseases 0.000 claims description 2
• 206010027476 Metastases Diseases 0.000 claims description 2
• 206010030113 Oedema Diseases 0.000 claims description 2
• 206010030155 Oesophageal carcinoma Diseases 0.000 claims description 2
• 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 2
• 206010033645 Pancreatitis Diseases 0.000 claims description 2
• 206010036049 Polycystic ovaries Diseases 0.000 claims description 2
• 208000004403 Prostatic Hyperplasia Diseases 0.000 claims description 2
• 201000004681 Psoriasis Diseases 0.000 claims description 2
• 102300033264 Receptor tyrosine-protein kinase erbB-2 isoform 1 Human genes 0.000 claims description 2
• 208000015634 Rectal Neoplasms Diseases 0.000 claims description 2
• 206010039491 Sarcoma Diseases 0.000 claims description 2
• 208000000453 Skin Neoplasms Diseases 0.000 claims description 2
• 208000025865 Ulcer Diseases 0.000 claims description 2
• 208000006593 Urologic Neoplasms Diseases 0.000 claims description 2
• 206010067269 Uterine fibrosis Diseases 0.000 claims description 2
• 230000001594 aberrant effect Effects 0.000 claims description 2
• 229940035674 anesthetics Drugs 0.000 claims description 2
• 239000000158 apoptosis inhibitor Substances 0.000 claims description 2
• 208000011775 arteriosclerosis disease Diseases 0.000 claims description 2
• 210000000941 bile Anatomy 0.000 claims description 2
• 208000026900 bile duct neoplasm Diseases 0.000 claims description 2
• 208000016886 cerebral arteriopathy with subcortical infarcts and leukoencephalopathy Diseases 0.000 claims description 2
• 208000006990 cholangiocarcinoma Diseases 0.000 claims description 2
• 208000029742 colonic neoplasm Diseases 0.000 claims description 2
• 230000001079 digestive effect Effects 0.000 claims description 2
• 230000002124 endocrine Effects 0.000 claims description 2
• 201000004101 esophageal cancer Diseases 0.000 claims description 2
• 208000024519 eye neoplasm Diseases 0.000 claims description 2
• 239000003193 general anesthetic agent Substances 0.000 claims description 2
• 201000011066 hemangioma Diseases 0.000 claims description 2
• 201000005787 hematologic cancer Diseases 0.000 claims description 2
• 208000024200 hematopoietic and lymphoid system neoplasm Diseases 0.000 claims description 2
• 201000006866 hypopharynx cancer Diseases 0.000 claims description 2
• 201000002313 intestinal cancer Diseases 0.000 claims description 2
• 201000007270 liver cancer Diseases 0.000 claims description 2
• 208000014018 liver neoplasm Diseases 0.000 claims description 2
• 229960005015 local anesthetics Drugs 0.000 claims description 2
• 210000004995 male reproductive system Anatomy 0.000 claims description 2
• 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 2
• 201000001441 melanoma Diseases 0.000 claims description 2
• 230000009401 metastasis Effects 0.000 claims description 2
• 210000005036 nerve Anatomy 0.000 claims description 2
• 208000015122 neurodegenerative disease Diseases 0.000 claims description 2
• 201000002528 pancreatic cancer Diseases 0.000 claims description 2
• 208000008443 pancreatic carcinoma Diseases 0.000 claims description 2
• 201000010065 polycystic ovary syndrome Diseases 0.000 claims description 2
• 206010038038 rectal cancer Diseases 0.000 claims description 2
• 201000001275 rectum cancer Diseases 0.000 claims description 2
• 206010039073 rheumatoid arthritis Diseases 0.000 claims description 2
• 201000000306 sarcoidosis Diseases 0.000 claims description 2
• 201000000980 schizophrenia Diseases 0.000 claims description 2
• 229940125723 sedative agent Drugs 0.000 claims description 2
• 201000000849 skin cancer Diseases 0.000 claims description 2
• 239000000021 stimulant Substances 0.000 claims description 2
• 231100000397 ulcer Toxicity 0.000 claims description 2
• 102000003800 Selectins Human genes 0.000 claims 2
• 108090000184 Selectins Proteins 0.000 claims 2
• AAEVYOVXGOFMJO-UHFFFAOYSA-N prometryn Chemical compound CSC1=NC(NC(C)C)=NC(NC(C)C)=N1 AAEVYOVXGOFMJO-UHFFFAOYSA-N 0.000 claims 2
• 208000021910 Cerebral Arterial disease Diseases 0.000 claims 1
• 206010061216 Infarction Diseases 0.000 claims 1
• 208000005016 Intestinal Neoplasms Diseases 0.000 claims 1
• 208000034800 Leukoencephalopathies Diseases 0.000 claims 1
• 201000009906 Meningitis Diseases 0.000 claims 1
• 229940127361 Receptor Tyrosine Kinase Inhibitors Drugs 0.000 claims 1
• 230000002491 angiogenic effect Effects 0.000 claims 1
• 230000007574 infarction Effects 0.000 claims 1
• 229940035363 muscle relaxants Drugs 0.000 claims 1
• 230000002739 subcortical effect Effects 0.000 claims 1
• 238000000034 method Methods 0.000 description 88
• 108090000623 proteins and genes Proteins 0.000 description 66
• 108010047041 Complementarity Determining Regions Proteins 0.000 description 65
• 235000018102 proteins Nutrition 0.000 description 57
• 102000004169 proteins and genes Human genes 0.000 description 57
• 239000000562 conjugate Substances 0.000 description 51
• 230000002195 synergetic effect Effects 0.000 description 47
• 239000000203 mixture Substances 0.000 description 44
• 210000004408 hybridoma Anatomy 0.000 description 39
• 239000000370 acceptor Substances 0.000 description 37
• 125000003275 alpha amino acid group Chemical group 0.000 description 27
• 230000000259 anti-tumor effect Effects 0.000 description 26
• 239000000523 sample Substances 0.000 description 24
• 241000699666 Mus <mouse, genus> Species 0.000 description 23
• 238000002965 ELISA Methods 0.000 description 20
• 238000004519 manufacturing process Methods 0.000 description 19
• 238000012216 screening Methods 0.000 description 19
• 241000699670 Mus sp. Species 0.000 description 17
• 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 description 17
• 238000012360 testing method Methods 0.000 description 17
• YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 16
• 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 description 16
• 239000013078 crystal Substances 0.000 description 15
• 230000005764 inhibitory process Effects 0.000 description 14
• 239000006228 supernatant Substances 0.000 description 14
• 241001465754 Metazoa Species 0.000 description 13
• 230000010261 cell growth Effects 0.000 description 13
• 108010021625 Immunoglobulin Fragments Proteins 0.000 description 12
• 102000008394 Immunoglobulin Fragments Human genes 0.000 description 12
• 235000001014 amino acid Nutrition 0.000 description 12
• 229940088598 enzyme Drugs 0.000 description 12
• 239000013604 expression vector Substances 0.000 description 12
• 238000001943 fluorescence-activated cell sorting Methods 0.000 description 12
• 102000004190 Enzymes Human genes 0.000 description 11
• 108090000790 Enzymes Proteins 0.000 description 11
• 230000004663 cell proliferation Effects 0.000 description 11
• UQLDLKMNUJERMK-UHFFFAOYSA-L di(octadecanoyloxy)lead Chemical compound [Pb+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O UQLDLKMNUJERMK-UHFFFAOYSA-L 0.000 description 11
• 229940127121 immunoconjugate Drugs 0.000 description 11
• 238000001727 in vivo Methods 0.000 description 11
• 239000002609 medium Substances 0.000 description 11
• 210000002966 serum Anatomy 0.000 description 11
• 108020004414 DNA Proteins 0.000 description 10
• 241000124008 Mammalia Species 0.000 description 10
• 230000004927 fusion Effects 0.000 description 10
• 210000004602 germ cell Anatomy 0.000 description 10
• 238000002156 mixing Methods 0.000 description 10
• 239000003981 vehicle Substances 0.000 description 10
• 238000013459 approach Methods 0.000 description 9
• 230000004071 biological effect Effects 0.000 description 9
• 229960002685 biotin Drugs 0.000 description 9
• 239000011616 biotin Substances 0.000 description 9
• 239000000126 substance Substances 0.000 description 9
• 230000001225 therapeutic effect Effects 0.000 description 9
• 210000001519 tissue Anatomy 0.000 description 9
• 102000001301 EGF receptor Human genes 0.000 description 8
• 108060006698 EGF receptor Proteins 0.000 description 8
• 235000020958 biotin Nutrition 0.000 description 8
• 239000012091 fetal bovine serum Substances 0.000 description 8
• 230000014509 gene expression Effects 0.000 description 8
• 239000001963 growth medium Substances 0.000 description 8
• 241000894007 species Species 0.000 description 8
• 230000005945 translocation Effects 0.000 description 8
• 210000004881 tumor cell Anatomy 0.000 description 8
• 230000004614 tumor growth Effects 0.000 description 8
• XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 8
• 206010055113 Breast cancer metastatic Diseases 0.000 description 7
• 125000000539 amino acid group Chemical group 0.000 description 7
• 238000004113 cell culture Methods 0.000 description 7
• 238000013508 migration Methods 0.000 description 7
• 230000005012 migration Effects 0.000 description 7
• 230000003472 neutralizing effect Effects 0.000 description 7
• 239000012071 phase Substances 0.000 description 7
• 101100112922 Candida albicans CDR3 gene Proteins 0.000 description 6
• LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
• 108091028043 Nucleic acid sequence Proteins 0.000 description 6
• 230000000996 additive effect Effects 0.000 description 6
• 238000004458 analytical method Methods 0.000 description 6
• 238000012054 celltiter-glo Methods 0.000 description 6
• 238000011284 combination treatment Methods 0.000 description 6
• 150000001875 compounds Chemical class 0.000 description 6
• 231100000673 dose–response relationship Toxicity 0.000 description 6
• 238000002474 experimental method Methods 0.000 description 6
• 230000002496 gastric effect Effects 0.000 description 6
• 239000000499 gel Substances 0.000 description 6
• 229910052739 hydrogen Inorganic materials 0.000 description 6
• 230000001965 increasing effect Effects 0.000 description 6
• 230000007246 mechanism Effects 0.000 description 6
• 239000000047 product Substances 0.000 description 6
• 238000003259 recombinant expression Methods 0.000 description 6
• 238000009097 single-agent therapy Methods 0.000 description 6
• 238000006467 substitution reaction Methods 0.000 description 6
• 108091003079 Bovine Serum Albumin Proteins 0.000 description 5
• KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 5
• 239000000611 antibody drug conjugate Substances 0.000 description 5
• 229940049595 antibody-drug conjugate Drugs 0.000 description 5
• 239000002299 complementary DNA Substances 0.000 description 5
• 238000012258 culturing Methods 0.000 description 5
• 238000010790 dilution Methods 0.000 description 5
• 239000012895 dilution Substances 0.000 description 5
• 230000012202 endocytosis Effects 0.000 description 5
• 238000009472 formulation Methods 0.000 description 5
• 238000004020 luminiscence type Methods 0.000 description 5
• 150000007523 nucleic acids Chemical class 0.000 description 5
• 230000004044 response Effects 0.000 description 5
• 230000002441 reversible effect Effects 0.000 description 5
• 239000000243 solution Substances 0.000 description 5
• 238000002560 therapeutic procedure Methods 0.000 description 5
• 238000012546 transfer Methods 0.000 description 5
• 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 4
• 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 description 4
• 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 description 4
• 241000282560 Macaca mulatta Species 0.000 description 4
• 108091007491 NSP3 Papain-like protease domains Proteins 0.000 description 4
• 206010061309 Neoplasm progression Diseases 0.000 description 4
• 241000700159 Rattus Species 0.000 description 4
• 239000000654 additive Substances 0.000 description 4
• 239000002671 adjuvant Substances 0.000 description 4
• 230000010056 antibody-dependent cellular cytotoxicity Effects 0.000 description 4
• 238000003556 assay Methods 0.000 description 4
• 230000008901 benefit Effects 0.000 description 4
• 230000015572 biosynthetic process Effects 0.000 description 4
• 230000000903 blocking effect Effects 0.000 description 4
• 210000004369 blood Anatomy 0.000 description 4
• 239000008280 blood Substances 0.000 description 4
• 230000037396 body weight Effects 0.000 description 4
• 238000006243 chemical reaction Methods 0.000 description 4
• 238000011161 development Methods 0.000 description 4
• 230000018109 developmental process Effects 0.000 description 4
• 230000013595 glycosylation Effects 0.000 description 4
• 238000006206 glycosylation reaction Methods 0.000 description 4
• 238000000338 in vitro Methods 0.000 description 4
• 230000003834 intracellular effect Effects 0.000 description 4
• 238000007912 intraperitoneal administration Methods 0.000 description 4
• 230000000670 limiting effect Effects 0.000 description 4
• 229920000642 polymer Polymers 0.000 description 4
• 238000002360 preparation method Methods 0.000 description 4
• 102000005962 receptors Human genes 0.000 description 4
• 108020003175 receptors Proteins 0.000 description 4
• 230000002829 reductive effect Effects 0.000 description 4
• 230000001105 regulatory effect Effects 0.000 description 4
• 229960001612 trastuzumab emtansine Drugs 0.000 description 4
• 230000005751 tumor progression Effects 0.000 description 4
• NFGXHKASABOEEW-UHFFFAOYSA-N 1-methylethyl 11-methoxy-3,7,11-trimethyl-2,4-dodecadienoate Chemical compound COC(C)(C)CCCC(C)CC=CC(C)=CC(=O)OC(C)C NFGXHKASABOEEW-UHFFFAOYSA-N 0.000 description 3
• 108090001008 Avidin Proteins 0.000 description 3
• 241000283707 Capra Species 0.000 description 3
• 108091026890 Coding region Proteins 0.000 description 3
• 241000196324 Embryophyta Species 0.000 description 3
• 241000588724 Escherichia coli Species 0.000 description 3
• 241000282412 Homo Species 0.000 description 3
• 101000611183 Homo sapiens Tumor necrosis factor Proteins 0.000 description 3
• 102000006496 Immunoglobulin Heavy Chains Human genes 0.000 description 3
• 108010019476 Immunoglobulin Heavy Chains Proteins 0.000 description 3
• 241000282553 Macaca Species 0.000 description 3
• 241000282567 Macaca fascicularis Species 0.000 description 3
• NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 description 3
• 206010061535 Ovarian neoplasm Diseases 0.000 description 3
• 229920001213 Polysorbate 20 Polymers 0.000 description 3
• 108010090804 Streptavidin Proteins 0.000 description 3
• 238000010171 animal model Methods 0.000 description 3
• 210000000628 antibody-producing cell Anatomy 0.000 description 3
• 239000012472 biological sample Substances 0.000 description 3
• 238000000006 cell growth inhibition assay Methods 0.000 description 3
• 230000008859 change Effects 0.000 description 3
• 238000012412 chemical coupling Methods 0.000 description 3
• 239000007795 chemical reaction product Substances 0.000 description 3
• 239000003153 chemical reaction reagent Substances 0.000 description 3
• 238000002512 chemotherapy Methods 0.000 description 3
• 210000004978 chinese hamster ovary cell Anatomy 0.000 description 3
• 238000002648 combination therapy Methods 0.000 description 3
• 238000013270 controlled release Methods 0.000 description 3
• 229920001577 copolymer Polymers 0.000 description 3
• 238000004132 cross linking Methods 0.000 description 3
• 230000003247 decreasing effect Effects 0.000 description 3
• 238000004925 denaturation Methods 0.000 description 3
• 230000036425 denaturation Effects 0.000 description 3
• 239000000539 dimer Substances 0.000 description 3
• 238000005516 engineering process Methods 0.000 description 3
• GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 3
• MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 3
• 230000006870 function Effects 0.000 description 3
• 230000036541 health Effects 0.000 description 3
• 229940022353 herceptin Drugs 0.000 description 3
• 230000001900 immune effect Effects 0.000 description 3
• 230000016784 immunoglobulin production Effects 0.000 description 3
• 229940051026 immunotoxin Drugs 0.000 description 3
• 230000002637 immunotoxin Effects 0.000 description 3
• 239000002596 immunotoxin Substances 0.000 description 3
• 231100000608 immunotoxin Toxicity 0.000 description 3
• 238000000099 in vitro assay Methods 0.000 description 3
• 238000001990 intravenous administration Methods 0.000 description 3
• 208000032839 leukemia Diseases 0.000 description 3
• 229910052757 nitrogen Inorganic materials 0.000 description 3
• 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 3
• 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 3
• 229940002612 prodrug Drugs 0.000 description 3
• 239000000651 prodrug Substances 0.000 description 3
• 238000000746 purification Methods 0.000 description 3
• 230000003248 secreting effect Effects 0.000 description 3
• 238000002198 surface plasmon resonance spectroscopy Methods 0.000 description 3
• 239000003053 toxin Substances 0.000 description 3
• 231100000765 toxin Toxicity 0.000 description 3
• 108700012359 toxins Proteins 0.000 description 3
• 238000001890 transfection Methods 0.000 description 3
• GANZODCWZFAEGN-UHFFFAOYSA-N 5-mercapto-2-nitro-benzoic acid Chemical compound OC(=O)C1=CC(S)=CC=C1[N+]([O-])=O GANZODCWZFAEGN-UHFFFAOYSA-N 0.000 description 2
• 108010088751 Albumins Chemical class 0.000 description 2
• 102000009027 Albumins Human genes 0.000 description 2
• 108020004774 Alkaline Phosphatase Proteins 0.000 description 2
• 102000002260 Alkaline Phosphatase Human genes 0.000 description 2
• IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
• 238000011729 BALB/c nude mouse Methods 0.000 description 2
• HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
• 230000004544 DNA amplification Effects 0.000 description 2
• BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 description 2
• 206010061818 Disease progression Diseases 0.000 description 2
• LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 2
• 108010010803 Gelatin Proteins 0.000 description 2
• 241000238631 Hexapoda Species 0.000 description 2
• 108010001336 Horseradish Peroxidase Proteins 0.000 description 2
• MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 2
• ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 2
• ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 2
• 102100029185 Low affinity immunoglobulin gamma Fc region receptor III-B Human genes 0.000 description 2
• 239000006137 Luria-Bertani broth Substances 0.000 description 2
• 108700020796 Oncogene Proteins 0.000 description 2
• 206010033128 Ovarian cancer Diseases 0.000 description 2
• 108010004729 Phycoerythrin Proteins 0.000 description 2
• 206010035226 Plasma cell myeloma Diseases 0.000 description 2
• 102000004022 Protein-Tyrosine Kinases Human genes 0.000 description 2
• 108090000412 Protein-Tyrosine Kinases Proteins 0.000 description 2
• 108700033844 Pseudomonas aeruginosa toxA Proteins 0.000 description 2
• 101710100968 Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 description 2
• JXLYSJRDGCGARV-WWYNWVTFSA-N Vinblastine Natural products O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@](O)(CC)C[C@H](C3)C4)cccc5)[C@@]32[C@H]2[C@@]1(CC)C=CCN2CC3)C JXLYSJRDGCGARV-WWYNWVTFSA-N 0.000 description 2
• RJURFGZVJUQBHK-UHFFFAOYSA-N actinomycin D Natural products CC1OC(=O)C(C(C)C)N(C)C(=O)CN(C)C(=O)C2CCCN2C(=O)C(C(C)C)NC(=O)C1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)NC4C(=O)NC(C(N5CCCC5C(=O)N(C)CC(=O)N(C)C(C(C)C)C(=O)OC4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-UHFFFAOYSA-N 0.000 description 2
• 229930013930 alkaloid Natural products 0.000 description 2
• 239000002168 alkylating agent Substances 0.000 description 2
• 229940100198 alkylating agent Drugs 0.000 description 2
• 229960000723 ampicillin Drugs 0.000 description 2
• AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 2
• 230000000202 analgesic effect Effects 0.000 description 2
• 210000004102 animal cell Anatomy 0.000 description 2
• 238000000137 annealing Methods 0.000 description 2
• 238000001574 biopsy Methods 0.000 description 2
• 210000001124 body fluid Anatomy 0.000 description 2
• 239000010839 body fluid Substances 0.000 description 2
• 210000004899 c-terminal region Anatomy 0.000 description 2
• 239000001506 calcium phosphate Substances 0.000 description 2
• 229910000389 calcium phosphate Inorganic materials 0.000 description 2
• 235000011010 calcium phosphates Nutrition 0.000 description 2
• 239000006285 cell suspension Substances 0.000 description 2
• 239000001913 cellulose Chemical class 0.000 description 2
• 229920002678 cellulose Chemical class 0.000 description 2
• 230000002490 cerebral effect Effects 0.000 description 2
• 239000011248 coating agent Substances 0.000 description 2
• 238000000576 coating method Methods 0.000 description 2
• 238000002967 competitive immunoassay Methods 0.000 description 2
• 230000000295 complement effect Effects 0.000 description 2
• 230000004540 complement-dependent cytotoxicity Effects 0.000 description 2
• 238000012790 confirmation Methods 0.000 description 2
• 230000021615 conjugation Effects 0.000 description 2
• 230000009260 cross reactivity Effects 0.000 description 2
• 235000018417 cysteine Nutrition 0.000 description 2
• 125000000151 cysteine group Chemical class N[C@@H](CS)C(=O)* 0.000 description 2
• 231100000433 cytotoxic Toxicity 0.000 description 2
• 230000001472 cytotoxic effect Effects 0.000 description 2
• 238000001514 detection method Methods 0.000 description 2
• 238000006471 dimerization reaction Methods 0.000 description 2
• 230000005750 disease progression Effects 0.000 description 2
• 150000004662 dithiols Chemical class 0.000 description 2
• 230000007783 downstream signaling Effects 0.000 description 2
• 210000003527 eukaryotic cell Anatomy 0.000 description 2
• 230000002538 fungal effect Effects 0.000 description 2
• 229920000159 gelatin Polymers 0.000 description 2
• 239000008273 gelatin Substances 0.000 description 2
• 235000019322 gelatine Nutrition 0.000 description 2
• 235000011852 gelatine desserts Nutrition 0.000 description 2
• 230000028993 immune response Effects 0.000 description 2
• 210000000987 immune system Anatomy 0.000 description 2
• 231100000110 immunotoxic Toxicity 0.000 description 2
• 230000002625 immunotoxic effect Effects 0.000 description 2
• 239000004615 ingredient Substances 0.000 description 2
• 238000002347 injection Methods 0.000 description 2
• 239000007924 injection Substances 0.000 description 2
• 238000001361 intraarterial administration Methods 0.000 description 2
• 239000003446 ligand Substances 0.000 description 2
• 210000004962 mammalian cell Anatomy 0.000 description 2
• 239000000463 material Substances 0.000 description 2
• 206010027191 meningioma Diseases 0.000 description 2
• 230000002503 metabolic effect Effects 0.000 description 2
• 206010061289 metastatic neoplasm Diseases 0.000 description 2
• 229960004857 mitomycin Drugs 0.000 description 2
• 230000035772 mutation Effects 0.000 description 2
• 201000000050 myeloid neoplasm Diseases 0.000 description 2
• 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 2
• 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 2
• 210000001672 ovary Anatomy 0.000 description 2
• 230000002018 overexpression Effects 0.000 description 2
• 230000036961 partial effect Effects 0.000 description 2
• 230000010412 perfusion Effects 0.000 description 2
• 229910052698 phosphorus Inorganic materials 0.000 description 2
• 210000002381 plasma Anatomy 0.000 description 2
• BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 2
• 229920001223 polyethylene glycol Polymers 0.000 description 2
• 210000001236 prokaryotic cell Anatomy 0.000 description 2
• AQHHHDLHHXJYJD-UHFFFAOYSA-N propranolol Chemical compound C1=CC=C2C(OCC(O)CNC(C)C)=CC=CC2=C1 AQHHHDLHHXJYJD-UHFFFAOYSA-N 0.000 description 2
• RXWNCPJZOCPEPQ-NVWDDTSBSA-N puromycin Chemical compound C1=CC(OC)=CC=C1C[C@H](N)C(=O)N[C@H]1[C@@H](O)[C@H](N2C3=NC=NC(=C3N=C2)N(C)C)O[C@@H]1CO RXWNCPJZOCPEPQ-NVWDDTSBSA-N 0.000 description 2
• 238000003127 radioimmunoassay Methods 0.000 description 2
• 229940124617 receptor tyrosine kinase inhibitor Drugs 0.000 description 2
• PYWVYCXTNDRMGF-UHFFFAOYSA-N rhodamine B Chemical compound [Cl-].C=12C=CC(=[N+](CC)CC)C=C2OC2=CC(N(CC)CC)=CC=C2C=1C1=CC=CC=C1C(O)=O PYWVYCXTNDRMGF-UHFFFAOYSA-N 0.000 description 2
• 230000019491 signal transduction Effects 0.000 description 2
• 150000003384 small molecules Chemical class 0.000 description 2
• 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 2
• 210000004988 splenocyte Anatomy 0.000 description 2
• 238000010561 standard procedure Methods 0.000 description 2
• 238000007920 subcutaneous administration Methods 0.000 description 2
• 239000013595 supernatant sample Substances 0.000 description 2
• 230000001988 toxicity Effects 0.000 description 2
• 231100000419 toxicity Toxicity 0.000 description 2
• QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 2
• 229960003048 vinblastine Drugs 0.000 description 2
• JXLYSJRDGCGARV-XQKSVPLYSA-N vincaleukoblastine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 JXLYSJRDGCGARV-XQKSVPLYSA-N 0.000 description 2
• 229960004528 vincristine Drugs 0.000 description 2
• OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 description 2
• OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 description 2
• HDTRYLNUVZCQOY-UHFFFAOYSA-N &alpha;-D-glucopyranosyl-&alpha;-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 1
• OZFAFGSSMRRTDW-UHFFFAOYSA-N (2,4-dichlorophenyl) benzenesulfonate Chemical compound ClC1=CC(Cl)=CC=C1OS(=O)(=O)C1=CC=CC=C1 OZFAFGSSMRRTDW-UHFFFAOYSA-N 0.000 description 1
• KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 1
• WHBMMWSBFZVSSR-GSVOUGTGSA-M (R)-3-hydroxybutyrate Chemical compound C[C@@H](O)CC([O-])=O WHBMMWSBFZVSSR-GSVOUGTGSA-M 0.000 description 1
• RTQWWZBSTRGEAV-PKHIMPSTSA-N 2-[[(2s)-2-[bis(carboxymethyl)amino]-3-[4-(methylcarbamoylamino)phenyl]propyl]-[2-[bis(carboxymethyl)amino]propyl]amino]acetic acid Chemical compound CNC(=O)NC1=CC=C(C[C@@H](CN(CC(C)N(CC(O)=O)CC(O)=O)CC(O)=O)N(CC(O)=O)CC(O)=O)C=C1 RTQWWZBSTRGEAV-PKHIMPSTSA-N 0.000 description 1
• UAIUNKRWKOVEES-UHFFFAOYSA-N 3,3',5,5'-tetramethylbenzidine Chemical compound CC1=C(N)C(C)=CC(C=2C=C(C)C(N)=C(C)C=2)=C1 UAIUNKRWKOVEES-UHFFFAOYSA-N 0.000 description 1
• FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
• YSFGBPCBPNVLOK-UHFFFAOYSA-N 6-hydroxy-2-methylhex-2-enamide Chemical compound NC(=O)C(C)=CCCCO YSFGBPCBPNVLOK-UHFFFAOYSA-N 0.000 description 1
• FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical class O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
• STQGQHZAVUOBTE-UHFFFAOYSA-N 7-Cyan-hept-2t-en-4,6-diinsaeure Natural products C1=2C(O)=C3C(=O)C=4C(OC)=CC=CC=4C(=O)C3=C(O)C=2CC(O)(C(C)=O)CC1OC1CC(N)C(O)C(C)O1 STQGQHZAVUOBTE-UHFFFAOYSA-N 0.000 description 1
• 206010003571 Astrocytoma Diseases 0.000 description 1
• 241000271566 Aves Species 0.000 description 1
• 231100000699 Bacterial toxin Toxicity 0.000 description 1
• 108010006654 Bleomycin Proteins 0.000 description 1
• 101100421423 Caenorhabditis elegans spl-1 gene Proteins 0.000 description 1
• GAGWJHPBXLXJQN-UORFTKCHSA-N Capecitabine Chemical compound C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1[C@H]1[C@H](O)[C@H](O)[C@@H](C)O1 GAGWJHPBXLXJQN-UORFTKCHSA-N 0.000 description 1
• GAGWJHPBXLXJQN-UHFFFAOYSA-N Capecitabine Natural products C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1C1C(O)C(O)C(C)O1 GAGWJHPBXLXJQN-UHFFFAOYSA-N 0.000 description 1
• 206010008342 Cervix carcinoma Diseases 0.000 description 1
• 206010008531 Chills Diseases 0.000 description 1
• 108010035532 Collagen Proteins 0.000 description 1
• 102000008186 Collagen Human genes 0.000 description 1
• 241000699802 Cricetulus griseus Species 0.000 description 1
• 229920001651 Cyanoacrylate Polymers 0.000 description 1
• 229920000858 Cyclodextrin Polymers 0.000 description 1
• 101150074155 DHFR gene Proteins 0.000 description 1
• 229940126161 DNA alkylating agent Drugs 0.000 description 1
• 238000007400 DNA extraction Methods 0.000 description 1
• 108010092160 Dactinomycin Proteins 0.000 description 1
• 108010002156 Depsipeptides Proteins 0.000 description 1
• 229920002307 Dextran Polymers 0.000 description 1
• 206010012646 Diabetic blindness Diseases 0.000 description 1
• 102100024746 Dihydrofolate reductase Human genes 0.000 description 1
• 108010053187 Diphtheria Toxin Proteins 0.000 description 1
• 102000016607 Diphtheria Toxin Human genes 0.000 description 1
• 239000012591 Dulbecco’s Phosphate Buffered Saline Substances 0.000 description 1
• 238000012286 ELISA Assay Methods 0.000 description 1
• 102000018651 Epithelial Cell Adhesion Molecule Human genes 0.000 description 1
• 108010066687 Epithelial Cell Adhesion Molecule Proteins 0.000 description 1
• 101001055311 Equus asinus Immunoglobulin heavy constant alpha Proteins 0.000 description 1
• 108090000371 Esterases Proteins 0.000 description 1
• 108091029865 Exogenous DNA Proteins 0.000 description 1
• 108010087819 Fc receptors Proteins 0.000 description 1
• 102000009109 Fc receptors Human genes 0.000 description 1
• 108010073385 Fibrin Proteins 0.000 description 1
• 102000009123 Fibrin Human genes 0.000 description 1
• BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 1
• 201000003741 Gastrointestinal carcinoma Diseases 0.000 description 1
• 208000032612 Glial tumor Diseases 0.000 description 1
• 206010018338 Glioma Diseases 0.000 description 1
• 102000006395 Globulins Human genes 0.000 description 1
• 108010044091 Globulins Proteins 0.000 description 1
• 239000004366 Glucose oxidase Substances 0.000 description 1
• 108010015776 Glucose oxidase Proteins 0.000 description 1
• 108090000288 Glycoproteins Proteins 0.000 description 1
• 102000003886 Glycoproteins Human genes 0.000 description 1
• 108010026389 Gramicidin Proteins 0.000 description 1
• 238000011460 HER2-targeted therapy Methods 0.000 description 1
• 208000031886 HIV Infections Diseases 0.000 description 1
• 208000017604 Hodgkin disease Diseases 0.000 description 1
• 208000021519 Hodgkin lymphoma Diseases 0.000 description 1
• 208000010747 Hodgkins lymphoma Diseases 0.000 description 1
• 101000690301 Homo sapiens Aldo-keto reductase family 1 member C4 Proteins 0.000 description 1
• 101000917826 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor II-a Proteins 0.000 description 1
• 101000917824 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor II-b Proteins 0.000 description 1
• 101000917858 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-A Proteins 0.000 description 1
• 101000917839 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-B Proteins 0.000 description 1
• 101001116548 Homo sapiens Protein CBFA2T1 Proteins 0.000 description 1
• 208000001953 Hypotension Diseases 0.000 description 1
• 108010073807 IgG Receptors Proteins 0.000 description 1
• 102000018071 Immunoglobulin Fc Fragments Human genes 0.000 description 1
• 108010091135 Immunoglobulin Fc Fragments Proteins 0.000 description 1
• 102000013463 Immunoglobulin Light Chains Human genes 0.000 description 1
• 108010065825 Immunoglobulin Light Chains Proteins 0.000 description 1
• 108010067060 Immunoglobulin Variable Region Proteins 0.000 description 1
• 102000017727 Immunoglobulin Variable Region Human genes 0.000 description 1
• 108010002350 Interleukin-2 Proteins 0.000 description 1
• QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
• AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 1
• QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
• OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
• NNJVILVZKWQKPM-UHFFFAOYSA-N Lidocaine Chemical compound CCN(CC)CC(=O)NC1=C(C)C=CC=C1C NNJVILVZKWQKPM-UHFFFAOYSA-N 0.000 description 1
• 102100029204 Low affinity immunoglobulin gamma Fc region receptor II-a Human genes 0.000 description 1
• 206010025323 Lymphomas Diseases 0.000 description 1
• KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
• 239000004472 Lysine Substances 0.000 description 1
• 102000043136 MAP kinase family Human genes 0.000 description 1
• 108091054455 MAP kinase family Proteins 0.000 description 1
• 208000015021 Meningeal Neoplasms Diseases 0.000 description 1
• MWCLLHOVUTZFKS-UHFFFAOYSA-N Methyl cyanoacrylate Chemical compound COC(=O)C(=C)C#N MWCLLHOVUTZFKS-UHFFFAOYSA-N 0.000 description 1
• 229930192392 Mitomycin Natural products 0.000 description 1
• WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 1
• 206010029113 Neovascularisation Diseases 0.000 description 1
• 206010029260 Neuroblastoma Diseases 0.000 description 1
• 208000005890 Neuroma Diseases 0.000 description 1
• 208000015914 Non-Hodgkin lymphomas Diseases 0.000 description 1
• 238000012408 PCR amplification Methods 0.000 description 1
• 108090000526 Papain Proteins 0.000 description 1
• 102000057297 Pepsin A Human genes 0.000 description 1
• 108090000284 Pepsin A Proteins 0.000 description 1
• 108010081690 Pertussis Toxin Proteins 0.000 description 1
• 231100000742 Plant toxin Toxicity 0.000 description 1
• 239000004698 Polyethylene Substances 0.000 description 1
• 239000002202 Polyethylene glycol Substances 0.000 description 1
• 229920001710 Polyorthoester Polymers 0.000 description 1
• 239000004365 Protease Substances 0.000 description 1
• 102000001253 Protein Kinase Human genes 0.000 description 1
• 206010037660 Pyrexia Diseases 0.000 description 1
• 108020004511 Recombinant DNA Proteins 0.000 description 1
• 208000017442 Retinal disease Diseases 0.000 description 1
• 201000000582 Retinoblastoma Diseases 0.000 description 1
• 206010038923 Retinopathy Diseases 0.000 description 1
• 108010083644 Ribonucleases Proteins 0.000 description 1
• 102000006382 Ribonucleases Human genes 0.000 description 1
• 108010039491 Ricin Proteins 0.000 description 1
• 238000011579 SCID mouse model Methods 0.000 description 1
• AUVVAXYIELKVAI-UHFFFAOYSA-N SJ000285215 Natural products N1CCC2=CC(OC)=C(OC)C=C2C1CC1CC2C3=CC(OC)=C(OC)C=C3CCN2CC1CC AUVVAXYIELKVAI-UHFFFAOYSA-N 0.000 description 1
• 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
• 235000014680 Saccharomyces cerevisiae Nutrition 0.000 description 1
• 108010084592 Saporins Proteins 0.000 description 1
• 206010040047 Sepsis Diseases 0.000 description 1
• 108010003723 Single-Domain Antibodies Proteins 0.000 description 1
• FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
• 229920002125 Sokalan® Polymers 0.000 description 1
• 229930006000 Sucrose Natural products 0.000 description 1
• CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
• 229940100514 Syk tyrosine kinase inhibitor Drugs 0.000 description 1
• 108091008874 T cell receptors Proteins 0.000 description 1
• 102000016266 T-Cell Antigen Receptors Human genes 0.000 description 1
• 210000001744 T-lymphocyte Anatomy 0.000 description 1
• 241000188156 Tamu Species 0.000 description 1
• 108010006785 Taq Polymerase Proteins 0.000 description 1
• 229940123237 Taxane Drugs 0.000 description 1
• AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
• 239000004473 Threonine Substances 0.000 description 1
• HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 1
• 102000004142 Trypsin Human genes 0.000 description 1
• 108090000631 Trypsin Proteins 0.000 description 1
• QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
• 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 1
• 208000002495 Uterine Neoplasms Diseases 0.000 description 1
• 201000004810 Vascular dementia Diseases 0.000 description 1
• 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
• 229940122803 Vinca alkaloid Drugs 0.000 description 1
• 244000195452 Wasabia japonica Species 0.000 description 1
• 235000000760 Wasabia japonica Nutrition 0.000 description 1
• SXEHKFHPFVVDIR-UHFFFAOYSA-N [4-(4-hydrazinylphenyl)phenyl]hydrazine Chemical compound C1=CC(NN)=CC=C1C1=CC=C(NN)C=C1 SXEHKFHPFVVDIR-UHFFFAOYSA-N 0.000 description 1
• 210000001015 abdomen Anatomy 0.000 description 1
• 230000002159 abnormal effect Effects 0.000 description 1
• OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical compound CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 description 1
• 229960004373 acetylcholine Drugs 0.000 description 1
• 238000005903 acid hydrolysis reaction Methods 0.000 description 1
• 230000002378 acidificating effect Effects 0.000 description 1
• RJURFGZVJUQBHK-IIXSONLDSA-N actinomycin D Chemical compound C[C@H]1OC(=O)[C@H](C(C)C)N(C)C(=O)CN(C)C(=O)[C@@H]2CCCN2C(=O)[C@@H](C(C)C)NC(=O)[C@H]1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)N[C@@H]4C(=O)N[C@@H](C(N5CCC[C@H]5C(=O)N(C)CC(=O)N(C)[C@@H](C(C)C)C(=O)O[C@@H]4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-IIXSONLDSA-N 0.000 description 1
• 230000009471 action Effects 0.000 description 1
• 239000004480 active ingredient Substances 0.000 description 1
• 239000000853 adhesive Substances 0.000 description 1
• 230000001070 adhesive effect Effects 0.000 description 1
• 238000001042 affinity chromatography Methods 0.000 description 1
• 239000011543 agarose gel Substances 0.000 description 1
• 206010064930 age-related macular degeneration Diseases 0.000 description 1
• 235000004279 alanine Nutrition 0.000 description 1
• 229940072056 alginate Drugs 0.000 description 1
• 229920000615 alginic acid Chemical class 0.000 description 1
• 235000010443 alginic acid Nutrition 0.000 description 1
• HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 1
• 230000003321 amplification Effects 0.000 description 1
• 230000003444 anaesthetic effect Effects 0.000 description 1
• 150000008064 anhydrides Chemical class 0.000 description 1
• 230000008485 antagonism Effects 0.000 description 1
• 239000003242 anti bacterial agent Substances 0.000 description 1
• 230000001093 anti-cancer Effects 0.000 description 1
• 230000001064 anti-interferon Effects 0.000 description 1
• 229940088710 antibiotic agent Drugs 0.000 description 1
• 238000011319 anticancer therapy Methods 0.000 description 1
• 238000011394 anticancer treatment Methods 0.000 description 1
• 229940030999 antipsoriatics Drugs 0.000 description 1
• 230000001640 apoptogenic effect Effects 0.000 description 1
• 230000006907 apoptotic process Effects 0.000 description 1
• 239000008346 aqueous phase Substances 0.000 description 1
• 230000003416 augmentation Effects 0.000 description 1
• VJBCNMFKFZIXHC-UHFFFAOYSA-N azanium;2-(4-methyl-5-oxo-4-propan-2-yl-1h-imidazol-2-yl)quinoline-3-carboxylate Chemical compound N.N1C(=O)C(C(C)C)(C)N=C1C1=NC2=CC=CC=C2C=C1C(O)=O VJBCNMFKFZIXHC-UHFFFAOYSA-N 0.000 description 1
• 239000000688 bacterial toxin Substances 0.000 description 1
• 210000002469 basement membrane Anatomy 0.000 description 1
• 230000001588 bifunctional effect Effects 0.000 description 1
• 210000000013 bile duct Anatomy 0.000 description 1
• 238000004166 bioassay Methods 0.000 description 1
• 239000012620 biological material Substances 0.000 description 1
• 229920001222 biopolymer Polymers 0.000 description 1
• 229960001561 bleomycin Drugs 0.000 description 1
• OYVAGSVQBOHSSS-UAPAGMARSA-O bleomycin A2 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C OYVAGSVQBOHSSS-UAPAGMARSA-O 0.000 description 1
• 210000000481 breast Anatomy 0.000 description 1
• 229960004117 capecitabine Drugs 0.000 description 1
• 239000000969 carrier Substances 0.000 description 1
• 238000013354 cell banking Methods 0.000 description 1
• 238000000423 cell based assay Methods 0.000 description 1
• 239000006143 cell culture medium Substances 0.000 description 1
• 230000030833 cell death Effects 0.000 description 1
• 230000024245 cell differentiation Effects 0.000 description 1
• 230000022534 cell killing Effects 0.000 description 1
• 210000000170 cell membrane Anatomy 0.000 description 1
• 230000001413 cellular effect Effects 0.000 description 1
• 206010008118 cerebral infarction Diseases 0.000 description 1
• 201000010881 cervical cancer Diseases 0.000 description 1
• 238000012512 characterization method Methods 0.000 description 1
• NDAYQJDHGXTBJL-MWWSRJDJSA-N chembl557217 Chemical compound C1=CC=C2C(C[C@H](NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](CC=3C4=CC=CC=C4NC=3)NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](CC=3C4=CC=CC=C4NC=3)NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](CC=3C4=CC=CC=C4NC=3)NC(=O)[C@@H](C(C)C)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](C(C)C)NC(=O)[C@H](C)NC(=O)[C@H](NC(=O)CNC(=O)[C@@H](NC=O)C(C)C)CC(C)C)C(=O)NCCO)=CNC2=C1 NDAYQJDHGXTBJL-MWWSRJDJSA-N 0.000 description 1
• 238000010382 chemical cross-linking Methods 0.000 description 1
• 201000000322 choriocarcinoma of ovary Diseases 0.000 description 1
• 238000003776 cleavage reaction Methods 0.000 description 1
• 238000010367 cloning Methods 0.000 description 1
• 230000004186 co-expression Effects 0.000 description 1
• 229920001436 collagen Polymers 0.000 description 1
• 229960005188 collagen Drugs 0.000 description 1
• 230000000112 colonic effect Effects 0.000 description 1
• 230000001447 compensatory effect Effects 0.000 description 1
• 230000002860 competitive effect Effects 0.000 description 1
• 239000008139 complexing agent Substances 0.000 description 1
• 238000004590 computer program Methods 0.000 description 1
• 238000007796 conventional method Methods 0.000 description 1
• 239000003431 cross linking reagent Substances 0.000 description 1
• 238000002425 crystallisation Methods 0.000 description 1
• 230000008025 crystallization Effects 0.000 description 1
• 239000012228 culture supernatant Substances 0.000 description 1
• 210000004748 cultured cell Anatomy 0.000 description 1
• UFULAYFCSOUIOV-UHFFFAOYSA-N cysteamine Chemical compound NCCS UFULAYFCSOUIOV-UHFFFAOYSA-N 0.000 description 1
• XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
• 206010052015 cytokine release syndrome Diseases 0.000 description 1
• 229960000640 dactinomycin Drugs 0.000 description 1
• 230000006378 damage Effects 0.000 description 1
• 229960000975 daunorubicin Drugs 0.000 description 1
• STQGQHZAVUOBTE-VGBVRHCVSA-N daunorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(C)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 STQGQHZAVUOBTE-VGBVRHCVSA-N 0.000 description 1
• 230000008260 defense mechanism Effects 0.000 description 1
• 230000006735 deficit Effects 0.000 description 1
• 238000013461 design Methods 0.000 description 1
• 230000037213 diet Effects 0.000 description 1
• 235000005911 diet Nutrition 0.000 description 1
• 230000029087 digestion Effects 0.000 description 1
• 108020001096 dihydrofolate reductase Proteins 0.000 description 1
• 238000010494 dissociation reaction Methods 0.000 description 1
• 230000005593 dissociations Effects 0.000 description 1
• 239000000890 drug combination Substances 0.000 description 1
• 238000007876 drug discovery Methods 0.000 description 1
• 230000009977 dual effect Effects 0.000 description 1
• 239000012636 effector Substances 0.000 description 1
• 229940121647 egfr inhibitor Drugs 0.000 description 1
• 238000004520 electroporation Methods 0.000 description 1
• AUVVAXYIELKVAI-CKBKHPSWSA-N emetine Chemical compound N1CCC2=CC(OC)=C(OC)C=C2[C@H]1C[C@H]1C[C@H]2C3=CC(OC)=C(OC)C=C3CCN2C[C@@H]1CC AUVVAXYIELKVAI-CKBKHPSWSA-N 0.000 description 1
• 229960002694 emetine Drugs 0.000 description 1
• 239000000839 emulsion Substances 0.000 description 1
• 239000003623 enhancer Substances 0.000 description 1
• 230000002708 enhancing effect Effects 0.000 description 1
• 230000002255 enzymatic effect Effects 0.000 description 1
• 210000002919 epithelial cell Anatomy 0.000 description 1
• 150000002148 esters Chemical class 0.000 description 1
• ZMMJGEGLRURXTF-UHFFFAOYSA-N ethidium bromide Chemical compound [Br-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CC)=C1C1=CC=CC=C1 ZMMJGEGLRURXTF-UHFFFAOYSA-N 0.000 description 1
• 229960005542 ethidium bromide Drugs 0.000 description 1
• VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 description 1
• 229960005420 etoposide Drugs 0.000 description 1
• 238000011156 evaluation Methods 0.000 description 1
• 238000013401 experimental design Methods 0.000 description 1
• 210000003608 fece Anatomy 0.000 description 1
• 229950003499 fibrin Drugs 0.000 description 1
• 238000009093 first-line therapy Methods 0.000 description 1
• 238000000684 flow cytometry Methods 0.000 description 1
• 239000012530 fluid Substances 0.000 description 1
• 238000002825 functional assay Methods 0.000 description 1
• 229940014259 gelatin Drugs 0.000 description 1
• 229960003297 gemtuzumab ozogamicin Drugs 0.000 description 1
• 201000008822 gestational choriocarcinoma Diseases 0.000 description 1
• 208000005017 glioblastoma Diseases 0.000 description 1
• 239000003862 glucocorticoid Substances 0.000 description 1
• 229940116332 glucose oxidase Drugs 0.000 description 1
• 235000019420 glucose oxidase Nutrition 0.000 description 1
• 150000004676 glycans Chemical class 0.000 description 1
• 239000003102 growth factor Substances 0.000 description 1
• 230000009036 growth inhibition Effects 0.000 description 1
• 208000019691 hematopoietic and lymphoid cell neoplasm Diseases 0.000 description 1
• 230000002440 hepatic effect Effects 0.000 description 1
• 239000000833 heterodimer Substances 0.000 description 1
• 238000005734 heterodimerization reaction Methods 0.000 description 1
• 239000000710 homodimer Substances 0.000 description 1
• 102000051957 human ERBB2 Human genes 0.000 description 1
• 102000054751 human RUNX1T1 Human genes 0.000 description 1
• 102000057041 human TNF Human genes 0.000 description 1
• 210000005260 human cell Anatomy 0.000 description 1
• 238000011577 humanized mouse model Methods 0.000 description 1
• 229920002674 hyaluronan Polymers 0.000 description 1
• 229960003160 hyaluronic acid Drugs 0.000 description 1
• 210000004754 hybrid cell Anatomy 0.000 description 1
• WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
• 230000036543 hypotension Effects 0.000 description 1
• 229960001001 ibritumomab tiuxetan Drugs 0.000 description 1
• 230000003100 immobilizing effect Effects 0.000 description 1
• 230000008076 immune mechanism Effects 0.000 description 1
• 230000036039 immunity Effects 0.000 description 1
• 238000003018 immunoassay Methods 0.000 description 1
• 230000009851 immunogenic response Effects 0.000 description 1
• 230000005847 immunogenicity Effects 0.000 description 1
• 238000003364 immunohistochemistry Methods 0.000 description 1
• 230000006872 improvement Effects 0.000 description 1
• 238000005462 in vivo assay Methods 0.000 description 1
• 238000011534 incubation Methods 0.000 description 1
• 238000001802 infusion Methods 0.000 description 1
• 238000011081 inoculation Methods 0.000 description 1
• 230000003993 interaction Effects 0.000 description 1
• 238000007918 intramuscular administration Methods 0.000 description 1
• 238000010253 intravenous injection Methods 0.000 description 1
• 238000007914 intraventricular administration Methods 0.000 description 1
• 238000002372 labelling Methods 0.000 description 1
• VQHSOMBJVWLPSR-JVCRWLNRSA-N lactitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-JVCRWLNRSA-N 0.000 description 1
• 239000000832 lactitol Substances 0.000 description 1
• 229960003451 lactitol Drugs 0.000 description 1
• 235000010448 lactitol Nutrition 0.000 description 1
• 210000000265 leukocyte Anatomy 0.000 description 1
• 229960004194 lidocaine Drugs 0.000 description 1
• 108020001756 ligand binding domains Proteins 0.000 description 1
• 239000007788 liquid Substances 0.000 description 1
• 230000007774 longterm Effects 0.000 description 1
• HWYHZTIRURJOHG-UHFFFAOYSA-N luminol Chemical compound O=C1NNC(=O)C2=C1C(N)=CC=C2 HWYHZTIRURJOHG-UHFFFAOYSA-N 0.000 description 1
• 210000004698 lymphocyte Anatomy 0.000 description 1
• 230000002934 lysing effect Effects 0.000 description 1
• 210000003712 lysosome Anatomy 0.000 description 1
• 230000001868 lysosomic effect Effects 0.000 description 1
• 208000002780 macular degeneration Diseases 0.000 description 1
• FPYJFEHAWHCUMM-UHFFFAOYSA-N maleic anhydride Chemical compound O=C1OC(=O)C=C1 FPYJFEHAWHCUMM-UHFFFAOYSA-N 0.000 description 1
• 208000022006 malignant tumor of meninges Diseases 0.000 description 1
• 239000004579 marble Substances 0.000 description 1
• 239000003550 marker Substances 0.000 description 1
• 108010082117 matrigel Proteins 0.000 description 1
• 238000005259 measurement Methods 0.000 description 1
• 229960003151 mercaptamine Drugs 0.000 description 1
• ANZJBCHSOXCCRQ-FKUXLPTCSA-N mertansine Chemical compound CO[C@@H]([C@@]1(O)C[C@H](OC(=O)N1)[C@@H](C)[C@@H]1O[C@@]1(C)[C@@H](OC(=O)[C@H](C)N(C)C(=O)CCS)CC(=O)N1C)\C=C\C=C(C)\CC2=CC(OC)=C(Cl)C1=C2 ANZJBCHSOXCCRQ-FKUXLPTCSA-N 0.000 description 1
• 229960005558 mertansine Drugs 0.000 description 1
• 230000001394 metastastic effect Effects 0.000 description 1
• 208000037819 metastatic cancer Diseases 0.000 description 1
• 208000011575 metastatic malignant neoplasm Diseases 0.000 description 1
• CFCUWKMKBJTWLW-BKHRDMLASA-N mithramycin Chemical compound O([C@@H]1C[C@@H](O[C@H](C)[C@H]1O)OC=1C=C2C=C3C[C@H]([C@@H](C(=O)C3=C(O)C2=C(O)C=1C)O[C@@H]1O[C@H](C)[C@@H](O)[C@H](O[C@@H]2O[C@H](C)[C@H](O)[C@H](O[C@@H]3O[C@H](C)[C@@H](O)[C@@](C)(O)C3)C2)C1)[C@H](OC)C(=O)[C@@H](O)[C@@H](C)O)[C@H]1C[C@@H](O)[C@H](O)[C@@H](C)O1 CFCUWKMKBJTWLW-BKHRDMLASA-N 0.000 description 1
• 239000003226 mitogen Substances 0.000 description 1
• 230000000394 mitotic effect Effects 0.000 description 1
• 229960001156 mitoxantrone Drugs 0.000 description 1
• KKZJGLLVHKMTCM-UHFFFAOYSA-N mitoxantrone Chemical compound O=C1C2=C(O)C=CC(O)=C2C(=O)C2=C1C(NCCNCCO)=CC=C2NCCNCCO KKZJGLLVHKMTCM-UHFFFAOYSA-N 0.000 description 1
• 230000004048 modification Effects 0.000 description 1
• 238000012986 modification Methods 0.000 description 1
• 238000001823 molecular biology technique Methods 0.000 description 1
• 238000012544 monitoring process Methods 0.000 description 1
• 239000000178 monomer Substances 0.000 description 1
• 230000002107 myocardial effect Effects 0.000 description 1
• ZTLGJPIZUOVDMT-UHFFFAOYSA-N n,n-dichlorotriazin-4-amine Chemical compound ClN(Cl)C1=CC=NN=N1 ZTLGJPIZUOVDMT-UHFFFAOYSA-N 0.000 description 1
• GKTNLYAAZKKMTQ-UHFFFAOYSA-N n-[bis(dimethylamino)phosphinimyl]-n-methylmethanamine Chemical compound CN(C)P(=N)(N(C)C)N(C)C GKTNLYAAZKKMTQ-UHFFFAOYSA-N 0.000 description 1
• 239000013642 negative control Substances 0.000 description 1
• 230000035407 negative regulation of cell proliferation Effects 0.000 description 1
• 208000007538 neurilemmoma Diseases 0.000 description 1
• 230000007935 neutral effect Effects 0.000 description 1
• 238000006386 neutralization reaction Methods 0.000 description 1
• 230000036963 noncompetitive effect Effects 0.000 description 1
• 238000010899 nucleation Methods 0.000 description 1
• 238000003199 nucleic acid amplification method Methods 0.000 description 1
• 108020004707 nucleic acids Proteins 0.000 description 1
• 102000039446 nucleic acids Human genes 0.000 description 1
• 239000002773 nucleotide Substances 0.000 description 1
• 125000003729 nucleotide group Chemical group 0.000 description 1
• 229920001542 oligosaccharide Polymers 0.000 description 1
• 150000002482 oligosaccharides Chemical class 0.000 description 1
• 210000000056 organ Anatomy 0.000 description 1
• 125000000962 organic group Chemical group 0.000 description 1
• 229960001756 oxaliplatin Drugs 0.000 description 1
• DWAFYCQODLXJNR-BNTLRKBRSA-L oxaliplatin Chemical compound O1C(=O)C(=O)O[Pt]11N[C@@H]2CCCC[C@H]2N1 DWAFYCQODLXJNR-BNTLRKBRSA-L 0.000 description 1
• 229940055729 papain Drugs 0.000 description 1
• 235000019834 papain Nutrition 0.000 description 1
• 244000052769 pathogen Species 0.000 description 1
• 230000001717 pathogenic effect Effects 0.000 description 1
• 239000008188 pellet Substances 0.000 description 1
• 229940111202 pepsin Drugs 0.000 description 1
• 102000013415 peroxidase activity proteins Human genes 0.000 description 1
• 108040007629 peroxidase activity proteins Proteins 0.000 description 1
• 238000002823 phage display Methods 0.000 description 1
• 230000003285 pharmacodynamic effect Effects 0.000 description 1
• 230000000144 pharmacologic effect Effects 0.000 description 1
• 210000003800 pharynx Anatomy 0.000 description 1
• 230000026731 phosphorylation Effects 0.000 description 1
• 238000006366 phosphorylation reaction Methods 0.000 description 1
• 239000003123 plant toxin Substances 0.000 description 1
• 239000013612 plasmid Substances 0.000 description 1
• 229910052697 platinum Inorganic materials 0.000 description 1
• 229960003171 plicamycin Drugs 0.000 description 1
• 229920001983 poloxamer Polymers 0.000 description 1
• 229920001308 poly(aminoacid) Polymers 0.000 description 1
• 229920000117 poly(dioxanone) Polymers 0.000 description 1
• 229920000747 poly(lactic acid) Polymers 0.000 description 1
• 229920001606 poly(lactic acid-co-glycolic acid) Polymers 0.000 description 1
• 239000002745 poly(ortho ester) Substances 0.000 description 1
• 229920001610 polycaprolactone Polymers 0.000 description 1
• 229920002704 polyhistidine Polymers 0.000 description 1
• 229920005862 polyol Polymers 0.000 description 1
• 150000003077 polyols Chemical class 0.000 description 1
• 229920001282 polysaccharide Polymers 0.000 description 1
• 239000005017 polysaccharide Substances 0.000 description 1
• 229920002451 polyvinyl alcohol Polymers 0.000 description 1
• 238000010837 poor prognosis Methods 0.000 description 1
• 230000003389 potentiating effect Effects 0.000 description 1
• 238000011533 pre-incubation Methods 0.000 description 1
• 238000001556 precipitation Methods 0.000 description 1
• 238000004321 preservation Methods 0.000 description 1
• 230000002265 prevention Effects 0.000 description 1
• 229960004919 procaine Drugs 0.000 description 1
• MFDFERRIHVXMIY-UHFFFAOYSA-N procaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1 MFDFERRIHVXMIY-UHFFFAOYSA-N 0.000 description 1
• 229960003712 propranolol Drugs 0.000 description 1
• 201000004240 prostatic hypertrophy Diseases 0.000 description 1
• 108060006633 protein kinase Proteins 0.000 description 1
• 238000001742 protein purification Methods 0.000 description 1
• 230000005180 public health Effects 0.000 description 1
• 229950010131 puromycin Drugs 0.000 description 1
• 230000002285 radioactive effect Effects 0.000 description 1
• 239000012857 radioactive material Substances 0.000 description 1
• 239000000941 radioactive substance Substances 0.000 description 1
• 238000001959 radiotherapy Methods 0.000 description 1
• 239000011541 reaction mixture Substances 0.000 description 1
• 238000011084 recovery Methods 0.000 description 1
• 210000000664 rectum Anatomy 0.000 description 1
• 230000009467 reduction Effects 0.000 description 1
• 238000011160 research Methods 0.000 description 1
• 238000012552 review Methods 0.000 description 1
• OHRURASPPZQGQM-GCCNXGTGSA-N romidepsin Chemical compound O1C(=O)[C@H](C(C)C)NC(=O)C(=C/C)/NC(=O)[C@H]2CSSCC\C=C\[C@@H]1CC(=O)N[C@H](C(C)C)C(=O)N2 OHRURASPPZQGQM-GCCNXGTGSA-N 0.000 description 1
• 238000010079 rubber tapping Methods 0.000 description 1
• 210000003296 saliva Anatomy 0.000 description 1
• 229920006395 saturated elastomer Polymers 0.000 description 1
• 206010039667 schwannoma Diseases 0.000 description 1
• 230000007017 scission Effects 0.000 description 1
• 230000028327 secretion Effects 0.000 description 1
• 230000001624 sedative effect Effects 0.000 description 1
• 230000001235 sensitizing effect Effects 0.000 description 1
• 238000000926 separation method Methods 0.000 description 1
• 238000012163 sequencing technique Methods 0.000 description 1
• 208000012201 sexual and gender identity disease Diseases 0.000 description 1
• 208000015891 sexual disease Diseases 0.000 description 1
• 230000001568 sexual effect Effects 0.000 description 1
• 230000011664 signaling Effects 0.000 description 1
• 238000003307 slaughter Methods 0.000 description 1
• PTLRDCMBXHILCL-UHFFFAOYSA-M sodium arsenite Chemical compound [Na+].[O-][As]=O PTLRDCMBXHILCL-UHFFFAOYSA-M 0.000 description 1
• 239000011780 sodium chloride Substances 0.000 description 1
• 238000009987 spinning Methods 0.000 description 1
• 210000000952 spleen Anatomy 0.000 description 1
• 238000003860 storage Methods 0.000 description 1
• 238000005728 strengthening Methods 0.000 description 1
• 239000005720 sucrose Substances 0.000 description 1
• 230000004654 survival pathway Effects 0.000 description 1
• 210000004243 sweat Anatomy 0.000 description 1
• 239000011885 synergistic combination Substances 0.000 description 1
• 238000003786 synthesis reaction Methods 0.000 description 1
• 230000002194 synthesizing effect Effects 0.000 description 1
• 238000002626 targeted therapy Methods 0.000 description 1
• 230000008685 targeting Effects 0.000 description 1
• NRUKOCRGYNPUPR-QBPJDGROSA-N teniposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@@H](OC[C@H]4O3)C=3SC=CC=3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 NRUKOCRGYNPUPR-QBPJDGROSA-N 0.000 description 1
• 229960001278 teniposide Drugs 0.000 description 1
• 229960002372 tetracaine Drugs 0.000 description 1
• GKCBAIGFKIBETG-UHFFFAOYSA-N tetracaine Chemical compound CCCCNC1=CC=C(C(=O)OCCN(C)C)C=C1 GKCBAIGFKIBETG-UHFFFAOYSA-N 0.000 description 1
• 231100001274 therapeutic index Toxicity 0.000 description 1
• 230000004797 therapeutic response Effects 0.000 description 1
• 125000003396 thiol group Chemical group [H]S* 0.000 description 1
• 150000003573 thiols Chemical class 0.000 description 1
• 229960005267 tositumomab Drugs 0.000 description 1
• 238000013518 transcription Methods 0.000 description 1
• 230000035897 transcription Effects 0.000 description 1
• 238000005829 trimerization reaction Methods 0.000 description 1
• 239000012588 trypsin Substances 0.000 description 1
• 230000005748 tumor development Effects 0.000 description 1
• OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
• 210000002700 urine Anatomy 0.000 description 1
• 206010046766 uterine cancer Diseases 0.000 description 1
• 210000001215 vagina Anatomy 0.000 description 1
• 230000002792 vascular Effects 0.000 description 1
• GBABOYUKABKIAF-GHYRFKGUSA-N vinorelbine Chemical compound C1N(CC=2C3=CC=CC=C3NC=22)CC(CC)=C[C@H]1C[C@]2(C(=O)OC)C1=CC([C@]23[C@H]([C@]([C@H](OC(C)=O)[C@]4(CC)C=CCN([C@H]34)CC2)(O)C(=O)OC)N2C)=C2C=C1OC GBABOYUKABKIAF-GHYRFKGUSA-N 0.000 description 1
• 229960002066 vinorelbine Drugs 0.000 description 1
• 238000003260 vortexing Methods 0.000 description 1
• 239000007762 w/o emulsion Substances 0.000 description 1
• 238000005406 washing Methods 0.000 description 1
• 230000003442 weekly effect Effects 0.000 description 1